OSI's ERF receptor inhibitor continues to demonstrate anticancer activity and good safety Sep. 15, 2000
Antibody and protein therapeutics for breast cancer sought by Eos and Biogen collaboration Sep. 15, 2000
Phase I clinical trials of Xcytrin begin for treatment of NSCLC and glioblastoma multiforme Sep. 13, 2000
RSS